Insulin and atherosclerosis

Hyperinsulinemia and atherosclerosis sit in uncomfortable proximity in people with type 2 diabetes and metabolic syndrome. Whether high insulin itself drives plaque formation has a more precise answer than most clinical discussions suggest.

What the mouse data show

Two complementary animal studies clarify the picture. In the first, researchers bred APOE-deficient mice with a global deletion of one insulin-receptor allele, raising circulating insulin 50-69% above normal through impaired clearance rather than reduced cell signaling. Per-cell insulin signaling, glucose tolerance, lipids, and blood pressure all remained unchanged. Atherosclerotic plaque showed no difference from controls [1]. Higher circulating insulin alone, in animals still insulin-sensitive at the cellular level, did not accelerate arterial disease.

The second study asked a different question. Researchers engineered mice so that only their macrophages lacked functional insulin receptors, while systemic metabolism stayed intact. On a high-cholesterol diet, these animals developed roughly 50% less atherosclerotic lesion area than controls [2]. Macrophages without insulin receptors produced far less LPS-stimulated IL-6 and IL-1β, meaning less inflammatory activation and fewer foam cells in the artery wall.

Read together, these findings are coherent. Higher insulin circulating through otherwise sensitive tissue does nothing to plaque. Insulin signaling localized to macrophages, however, amplifies their pro-inflammatory behavior enough to account for half of plaque formation in this model [1] [2].

Why insulin resistance changes everything

Verhoeven's analysis suggests the atherogenic effect operates through a specific bypass mechanism [3]. In insulin-resistant individuals, cells downregulate insulin receptors, but IGF-1 receptors remain available. At the high insulin concentrations seen in insulin resistance, insulin can bind IGF-1 receptors and activate the ERK/IRK pathway, promoting smooth muscle cell migration and plaque progression. This bypass does not occur in insulin-sensitive people, which explains why the global haploinsufficiency mice in Study 1 showed no excess plaque despite sky-high insulin levels. Verhoeven's analysis notes this IGF-1 receptor pathway is the proposed mechanism for harm in hyperinsulinemic, insulin-resistant states, though no direct primary evidence yet confirms it in humans [3].

What this means in clinical context

The practical distinctions matter. A person with type 1 diabetes using physiologic insulin doses (around 35 units per day) is unlikely to face added plaque risk from insulin itself, because insulin sensitivity at the cellular level remains intact. The picture shifts for type 2 diabetics requiring hyperphysiologic doses (75-150+ units per day) in the context of established insulin resistance. There, Verhoeven's analysis flags a likely atherogenic trade-off between glucose control and vascular health [3]. For people in pre-diabetic states, chronically improved endogenous insulin operating against a background of insulin resistance may carry similar vascular implications.

Diabetes researcher Dr. Ralph DeFronzo has argued, as cited in Verhoeven's analysis, that high insulin levels are atherogenic [3]. The mouse evidence partially supports his concern, but the framing requires precision. The mechanism runs through insulin resistance as a necessary co-factor, not through circulating insulin concentration alone.

Where the evidence is contested

The primary limitation is species: both key studies are mouse models [1] [2]. Causal evidence in humans is absent. Mouse atherosclerosis models reproduce some features of human plaque but differ in important ways, and the macrophage-specific knockout findings have not been reproduced in human tissue or clinical trials.

The IGF-1 receptor bypass mechanism proposed to explain harm in insulin-resistant states is analyst-level analyst synthesis only [3]. It is mechanistically plausible and consistent with the animal data, but it has not been tested directly in humans. Clinicians who emphasize insulin as independently atherogenic and those who place the risk entirely in insulin resistance are working from the same thin human evidence base. The mouse data favor the insulin-resistance-dependent framing, but that conclusion does not carry to human cardiovascular risk without reservation.

References

1. Rask-Madsen 2012 — Hyperinsulinemia does NOT change atherosclerosis in apoE-/- · PubMed 22426129
2. Baumgartl 2006 — Macrophage IR KO in apoE-/- → ~50% lesion reduction · PubMed 16581002
3. raw/physionic/physionic-cac-zero-dont-be-fooled.txt